The SEC (U.S. securities regulator) and FDA (U.S. medicines regulator) signed a three-year memorandum of understanding on Aug. 31, 2026, creating formal channels to exchange nonpublic information about regulated products, public companies and potential legal violations. The agreement took effect immediately and permits the SEC to use FDA information in filing reviews, enforcement investigations, administrative proceedings and civil actions. It does not announce an investigation, new disclosure rule or enforcement case against any company, but creates procedures for comparing corporate statements with FDA records. The agencies said the arrangement should strengthen regulatory cooperation, transparency and market oversight, particularly for biotechnology, pharmaceutical, medical-device and healthcare companies whose trial results, FDA submissions, reviews and approvals can affect stock prices. Nonpublic records remain subject to confidentiality safeguards, trade-secret and confidential-commercial-information restrictions, written-permission requirements and existing legal privileges. The MOU does not grant new statutory powers, covers only requests submitted after Aug. 31, and excludes public-record requests, subpoenas and testimony. Either agency may terminate it with 30 days' notice, while an extension or modification requires mutual written consent; absent an extension, it expires in August 2029.